In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance

Many drugs are effective in the early stage of treatment, but patients develop drug resistance after a certain period of treatment, causing failure of the therapy. An important example is Herceptin, a popular monoclonal antibody drug for breast cancer by specifically targeting human epidermal growth factor receptor 2 (Her2). Here we demonstrate a quantitative binding kinetics analysis of drug-target interactions to investigate the molecular scale origin of drug resistance. Using a surface plasmon resonance imaging, we measured the in situ Herceptin-Her2 binding kinetics in single intact cancer cells for the first time, and observed significantly weakened Herceptin-Her2 interactions in Herceptin-resistant cells, compared to those in Herceptin-sensitive cells. We further showed that the steric hindrance of Mucin-4, a membrane protein, was responsible for the altered drug-receptor binding. This effect of a third molecule on drug-receptor interactions cannot be studied using traditional purified protein methods, demonstrating the importance of the present intact cell-based binding kinetics analysis.

[1]  G. Hortobagyi,et al.  Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.

[2]  R. Darling,et al.  Kinetic exclusion assay technology: characterization of molecular interactions. , 2004, Assay and drug development technologies.

[3]  P. Rudland,et al.  Rat Muc4 (sialomucin complex) reduces binding of anti‐ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance , 2002, International journal of cancer.

[4]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[5]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[6]  F. Bosch,et al.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.

[7]  Peter W Muncaster.  Chapter 2 – Advantages and applications , 1991 .

[8]  G. D'alessio,et al.  Differential binding of human immunoagents and Herceptin to the ErbB2 receptor , 2008, The FEBS journal.

[9]  A. Christopoulos.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[10]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[11]  J. Isola,et al.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. , 2005, Cancer research.

[12]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  R. Wallace.  Novel targets for drug discovery , 1996 .

[14]  Yunze Yang,et al.  Label-free measuring and mapping of binding kinetics of membrane proteins in single living cells. , 2012, Nature chemistry.

[15]  P. Rathanaswami,et al.  High-affinity binding measurements of antibodies to cell-surface-expressed antigens. , 2008, Analytical biochemistry.

[16]  M. Willingham,et al.  Development of Herceptin resistance in breast cancer cells , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[17]  T. Glass,et al.  Measurement of the functional affinity constant of a monoclonal antibody for cell surface receptors using kinetic exclusion fluorescence immunoassay. , 2005, Journal of immunological methods.

[18]  W Lucas,et al.  Advantages and applications , 1990 .

[19]  D. Swinney.  The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.

[20]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[21]  P. Deprez,et al.  PANCREATITIS INDUCED BY 5-AMINOSALICYLIC ACID , 1989, The Lancet.

[22]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[23]  John G Doench,et al.  Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells. , 2005, Cold Spring Harbor symposia on quantitative biology.

[24]  U. Rant,et al.  Quantitation of affinity, avidity, and binding kinetics of protein analytes with a dynamically switchable biosurface. , 2012, Journal of the American Chemical Society.

[25]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[26]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.